Ethoxyquin prevents chemotherapy-induced neurotoxicity via Hsp90 modulation

Annals of Neurology

Volumn 74, Issue 6, 2013, Pages 893-904

  Zhu, Jing ^a   Chen, Weiran ^a   Mi, Ruifa ^a   Zhou, Chunhua ^a   Reed, Nicole ^a   Höke, Ahmet ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETHOXYQUIN; HEAT SHOCK PROTEIN 90; NEUROPROTECTIVE AGENT; PACLITAXEL;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY; CONTROLLED STUDY; DRUG MECHANISM; DRUG SCREENING; EMBRYO; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NERVE FIBER DEGENERATION; NEUROPROTECTION; NONHUMAN; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RAT;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; AXONS; CELL LINE; DRUG EVALUATION, PRECLINICAL; ETHOXYQUIN; HSP90 HEAT-SHOCK PROTEINS; MALE; MICE; NERVE DEGENERATION; NEURONS; NEUROPROTECTIVE AGENTS; NEUROTOXICITY SYNDROMES; PACLITAXEL;

EID: 84892916127     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.24004     Document Type: Article

References (46)

1. McGuire WP, Rowinsky EK, Rosenshein NB, et al. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 1989; 111: 273-279.
2. Rowinsky EK, Donehower RC,. Paclitaxel (Taxol). N Engl J Med 1995; 332: 1004-1014.
3. Holmes FA, Walters RS, Theriault RL, et al. Phase II trial of Taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 1991; 83: 1797-1805.
4. Forastiere AA, Neuberg D, Taylor SG IV, et al. Phase II evaluation of Taxol in advanced head and neck cancer: an Eastern Cooperative Oncology group trial. J Natl Cancer Inst Monogr 1993;(15): 181-184.
5. Murphy WK, Fossella FV, Winn RJ, et al. Phase II study of Taxol in patients with untreated advanced non-small-cell lung cancer. J Natl Cancer Inst 1993; 85: 384-388.
6. Apfel SC,. Managing the neurotoxicity of paclitaxel (Taxol) and docetaxel (Taxotere) with neurotrophic factors. Cancer Invest 2000; 18: 564-573.
7. Rowinsky EK, Chaudhry V, Cornblath DR, Donehower RC,. Neurotoxicity of Taxol. J Natl Cancer Inst Monogr 1993;(15): 107-115.
8. Chen W, Mi R, Haughey N, et al. Immortalization and characterization of a nociceptive dorsal root ganglion sensory neuronal line. J Peripher Nerv Syst 2007; 12: 121-130.
9. Keswani SC, Chander B, Hasan C, et al. FK506 is neuroprotective in a model of antiretroviral toxic neuropathy. Ann Neurol 2003; 53: 57-64.
10. Melli G, Jack C, Lambrinos GL, et al. Erythropoietin protects sensory axons against paclitaxel-induced distal degeneration. Neurobiol Dis 2006; 24: 525-530.
11. McArthur JC, Stocks EA, Hauer P, et al. Epidermal nerve fiber density: normative reference range and diagnostic efficiency. Arch Neurol 1998; 55: 1513-1520.
12. Klauber N, Parangi S, Flynn E, et al. Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and Taxol. Cancer Res 1997; 57: 81-86.
13. Rowlands MG, Newbatt YM, Prodromou C, et al. High-throughput screening assay for inhibitors of heat-shock protein 90 ATPase activity. Anal Biochem 2004; 327: 176-183.
14. Chen Y, Muller JD, Tetin SY, et al. Probing ligand protein binding equilibria with fluorescence fluctuation spectroscopy. Biophys J 2000; 79: 1074-1084.
15. Bodenreider C, Beer D, Keller TH, et al. A fluorescence quenching assay to discriminate between specific and nonspecific inhibitors of dengue virus protease. Anal Biochem 2009; 395: 195-204.
16. Koul A, Dendouga N, Vergauwen K, et al. Diarylquinolines target subunit c of mycobacterial ATP synthase. Nat Chem Biol 2007; 3: 323-324.
17. Shelton SN, Shawgo ME, Matthews SB, et al. KU135, a novel novobiocin-derived C-terminal inhibitor of the 90-kDa heat shock protein, exerts potent antiproliferative effects in human leukemic cells. Mol Pharmacol 2009; 76: 1314-1322.
18. Donnelly A, Blagg BS,. Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket. Curr Med Chem 2008; 15: 2702-2717.
19. Burlison JA, Neckers L, Smith AB, et al. Novobiocin: redesigning a DNA gyrase inhibitor for selective inhibition of hsp90. J Am Chem Soc 2006; 128: 15529-15536.
20. Batulan Z, Taylor DM, Aarons RJ, et al. Induction of multiple heat shock proteins and neuroprotection in a primary culture model of familial amyotrophic lateral sclerosis. Neurobiol Dis 2006; 24: 213-225.
21. Luo W, Sun W, Taldone T, et al. Heat shock protein 90 in neurodegenerative diseases. Mol Neurodegener 2010; 5: 24.
22. Jego G, Hazoume A, Seigneuric R, Garrido C,. Targeting heat shock proteins in cancer. Cancer Lett 2013; 332: 275-285.
23. Byrd CA, Bornmann W, Erdjument-Bromage H, et al. Heat shock protein 90 mediates macrophage activation by Taxol and bacterial lipopolysaccharide. Proc Natl Acad Sci U S A 1999; 96: 5645-5650.
24. Comfort A, Youhotsky-Gore I, Pathmanathan K,. Effect of ethoxyquin on the longevity of C3H mice. Nature 1971; 229: 254-255.
25. Wattenberg LW,. Inhibition of chemical carcinogenesis. J Natl Cancer Inst 1978; 60: 11-18.
26. Thorisson S, Gunstone FD, Hardy R,. Some oxidation products of ethoxyquin including those found in autoxidising systems. Chem Phys Lipids 1992; 60: 263-271.
27. Thorisson S,. Antioxidant properties of ethoxyquin and some of its oxidation products. St Andrews: University of St Andrews, 1987.
28. Bukau B, Weissman J, Horwich A,. Molecular chaperones and protein quality control. Cell 2006; 125: 443-451.
29. Hartl FU, Hayer-Hartl M,. Molecular chaperones in the cytosol: from nascent chain to folded protein. Science 2002; 295: 1852-1858.
30. Hong DS, Banerji U, Tavana B, et al. Targeting the molecular chaperone heat shock protein 90 (HSP90): lessons learned and future directions. Cancer Treat Rev 2013; 39: 375-387.
31. Miyata Y, Koren J, Kiray J, et al. Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies. Future Med Chem 2011; 3: 1523-1537.
32. Pulst SM, Nechiporuk A, Nechiporuk T, et al. Moderate expansion of a normally biallelic trinucleotide repeat in spinocerebellar ataxia type 2. Nat Genet 1996; 14: 269-276.
33. Elden AC, Kim HJ, Hart MP, et al. Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature 2010; 466: 1069-1075.
34. Golas MM, Sander B, Will CL, et al. Molecular architecture of the multiprotein splicing factor SF3b. Science 2003; 300: 980-984.
35. Belzil VV, Gendron TF, Petrucelli L,. RNA-mediated toxicity in neurodegenerative disease. Mol Cell Neurosci 2013; 56C: 406-419.
36. Neumann M, Sampathu DM, Kwong LK, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 2006; 314: 130-133.
37. Vance C, Rogelj B, Hortobagyi T, et al. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science 2009; 323: 1208-1211.
38. Kwiatkowski TJ Jr, Bosco DA, Leclerc AL, et al. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science 2009; 323: 1205-1208.
39. Urban MJ, Pan P, Farmer KL, et al. Modulating molecular chaperones improves sensory fiber recovery and mitochondrial function in diabetic peripheral neuropathy. Exp Neurol 2012; 235: 388-396.
40. Carozzi VA, Canta A, Oggioni N, et al. Neurophysiological and neuropathological characterization of new murine models of chemotherapy-induced chronic peripheral neuropathies. Exp Neurol 2010; 226: 301-309.
41. Wang MS, Davis AA, Culver DG, et al. Calpain inhibition protects against Taxol-induced sensory neuropathy. Brain 2004; 127 (pt 3): 671-679.
42. Wang MS, Davis AA, Culver DG, Glass JD,. WldS mice are resistant to paclitaxel (Taxol) neuropathy. Ann Neurol 2002; 52: 442-447.
43. Melli G, Taiana M, Camozzi F, et al. Alpha-lipoic acid prevents mitochondrial damage and neurotoxicity in experimental chemotherapy neuropathy. Exp Neurol 2008; 214: 276-284.
44. Jin HW, Flatters SJ, Xiao WH, et al. Prevention of paclitaxel-evoked painful peripheral neuropathy by acetyl-L-carnitine: effects on axonal mitochondria, sensory nerve fiber terminal arbors, and cutaneous Langerhans cells. Exp Neurol 2008; 210: 229-237.
45. Xiao WH, Zheng FY, Bennett GJ, et al. Olesoxime (cholest-4-en-3-one, oxime): analgesic and neuroprotective effects in a rat model of painful peripheral neuropathy produced by the chemotherapeutic agent, paclitaxel. Pain 2009; 147: 202-209.
46. Carozzi VA, Chiorazzi A, Canta A, et al. Glutamate carboxypeptidase inhibition reduces the severity of chemotherapy-induced peripheral neurotoxicity in rat. Neurotox Res 2010; 17: 380-391.